International Clinical Trial: A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07739199) titled 'A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)' on July 28.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Condition: Squamous Non-small-cell Lung Cancer

Intervention: Drug: BL-B01D1 Drug: PD-1/VEGF bispecific antibody Drug: Paclitaxel

Re...